PCM
BDTX icon

Peregrine Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Peregrine Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-184,253
Closed -$4.47M – 338
2021
Q1 		$4.47M Sell
184,253
-25,658
-12% -$692K 0.08% 256
2020
Q4 		$6.73M Buy
209,911
+18,411
+10% +$605K 0.13% 249
2020
Q3 		$5.79M Buy
+191,500
New +$5.83M 0.15% 211

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Peregrine Capital Management's BDTX Position: Q2 2021 in Review

Peregrine Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 184,253 shares — an estimated $4.47M sold.

Peregrine Capital Management first reported a position in BDTX in Q3 2020 and held it in 3 quarters. The position peaked at $6.73M in Q4 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Peregrine Capital Management reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 184,253 Black Diamond Therapeutics shares in Q2 2021, an estimated $4.47M.
  • Peregrine Capital Management first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 3 quarters.
  • Peregrine Capital Management's Black Diamond Therapeutics position peaked at $6.73M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Peregrine Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.